Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines’ $273 million fundraise
(Reuters) – Drug developer Generate:Biomedicines, which uses artificial intelligence (AI)
amgen
US judge hearing fight over Amgen deal for Horizon eyes September trial
CHICAGO (Reuters) – The judge who will decide if Amgen
Amgen wins appeal in US patent case over generic psoriasis drugs
By Blake Brittain (Reuters) – Amgen Inc convinced a U.S.
Amgen emerges frontrunner in Horizon deal as Sanofi drops bid
(Reuters) -Amgen Inc is in advanced talks to buy biotech
Amgen says experimental obesity drug has promising durability
By Deena Beasley LOS ANGELES (Reuters) – Amgen Inc’s experimental
Amgen says Lumakras cuts risk of lung cancer progression by 34%
By Deena Beasley (Reuters) – Amgen Inc’s Lumakras pill reduced
Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
By Michael Erman NEW YORK – The U.S. Senate Finance
Amgen drug extends survival in some inoperable colon cancers
By Nancy Lapid (Reuters) – The following are summaries of